DRAGON Trial

Advertisement

cGxPJobs Banner

Belite Bio Reports Positive Phase 3 Tinlarebant Data at ASRS 2026

SAN DIEGO, July 20, 2026 Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase...

By cGxPwire Editor
July 21, 2026

Read More

Belite Bio Highlights DRAGON Trial at ISCEV and ASRS

SAN DIEGO, July 6, 2026 Belite Bio announced that new clinical data from its Phase 3 DRAGON trial evaluating...

By cGxPwire Editor
July 8, 2026

Read More

Advertisement

cGxPJobs

Directory